Charlottesville, VA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The University of Virginia (UVA) today announced the signing of a Master Research Collaboration Agreement with AstraZeneca designed to expedite pre-clinical research partnerships between the global biopharmaceutical company and UVA’s schools and departments. The agreement streamlines processes and enables AstraZeneca’s research and development teams to work more effectively and efficiently across UVA’s breadth of scientific expertise, infrastructure and ...

First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg’s potential best-in-class profile in relapsed/refractory CLL 83% objective overall response rate and progression free survival of 22.1 months demonstrate durable therapeutic effects in a large portion of patients Presented differentiated preclinical data for IRAK4 degrader GS-6791 in collaboration with Gilead Well capitalized with cash and marke ...

For smaller-volume, at-home administration, Halozyme highlighted Hypercon and Surf Bio, which management said can enable hyperconcentration of therapeutics up to approximately 500 mg/mL—potentially reducing injection volumes to less than 2 mL or into a 2 mL to 10 mL range that could fit either a small-volume autoinjector or Halozyme’s proprietary high-volume autoinjector.Torley also pointed to two areas of emerging interest for ENHANZE: potential applications with nucleic acids (including interest in lipid ...

As filed with the Securities and Exchange Commission on January 28, 2026. Registration No. 333-292657 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Veradermics, Incorporated (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 84-3304423 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identificat ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Tyligand Bioscience Ltd. 泰勵生物有限公司 * (the "Company") (Incorporated in the Cayman Islands with limited liability) WARNING The publication ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Suzhou Genhouse Bio Co., Ltd. 勤浩醫藥（蘇州）股份有限公司 (A joint stock company incorporated in the People's Republic of China with limited liability) WARNING ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Tyligand Bioscience Ltd. 泰勵生物有限公司* (Incorporated in the Cayman Islands with limited liability) WARNING The publication of this announcement is req ...

Key Takeaways FDA lifts clinical hold on NTLA's MAGNITUDE-2 phase III IND for nex-z in ATTRv-PN, enabling study resumption.NTLA aligned with the FDA on study changes and liver monitoring. It plans to resume enrollment and dosing.Nex-z is Intellia's lead program, in partnership with Regeneron, which shares 25% of R&D costs and profits.Intellia Therapeutics (NTLA) announced that the FDA lifted the clinical hold on the investigational new drug application (IND) for the phase III study, MAGNITUDE-2, evaluating ...

SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today issued a statement to address recent statements containing inaccurate and misleading claims regarding the Company’s resear ...

We came across a bullish thesis on argenx SE on Lux Opes Research’s Substack. In this article, we will summarize the bulls’ thesis on ARGX. argenx SE's share was trading at $833.16 as of January 26th. ARGX’s trailing and forward P/E were 35.64 and 27.93 respectively according to Yahoo Finance. Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress Copyright: nexusplexus / 123RF Stock Photo argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of ...